Table 1.

Clinical cohorts included in the study

CohortStand Up To Cancer (SU2C)
Foundation Medicine (FM)MDACCMSKCCDFCI/MGHCheckmate-057 (CM-057)MDACC (PD-L1 ≥ 1%)
N924 (346 KRASMUT)174
6256564466
NivolumabNA1462416
PembrolizumabNA19NA40
AtezolizumabNA0NA5
anti-PD(L)-1 + anti-CTLA4NA9NA3
DocetaxelNANA20NA
OtherNANANA2a
  • aOne patient with STK11/LKB1–mutant tumor was treated with nivolumab and NKTR-214 (CD122-based agonist) and one patient with STK11/LKB1 wild-type tumor was treated with pembrolizumab and OX40 agonist.